{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-013290","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.517350+00:00","generated_at":"2026-06-16T11:16:01.760551+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sangamo cuts 27% of US workforce, restructures toward neurology and Fabry; EVP departs","bullets":["US workforce reduced by ~120 roles (~27%); expects ~$31M annualized cost savings from restructuring.","EVP Technical Operations R. Andrew Ramelmeier to leave July 10, 2023; Phillip Ramsey appointed Head of Technical Ops.","Preliminary Q1 cash position expected to fund operations for at least 12 months; full Q1 results due by May 10, 2023.","Strategic focus on Nav1.7 (IND 2024), prion (IND 2025), Fabry Phase 3 trial, and TX200 CAR-Treg; pauses partnered programs.","One-time restructuring costs estimated at $5M-$7M, primarily in Q2 2023; reduces internal manufacturing and allogeneic footprints."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-013290","json":"https://secwatch.observer/filing/0001628280-23-013290.json","markdown":"https://secwatch.observer/filing/0001628280-23-013290.md","text":"https://secwatch.observer/filing/0001628280-23-013290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/sgmo-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:16:01.760551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55925395dca8941d18ee9d5bc3a3a6c5df9d9a49","claim":"SANGAMO THERAPEUTICS, INC reported preliminary financial results for first quarter 2023.","evidence_excerpt":"Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing preliminary financial results for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ecdffc0296","claim":"R. Andrew Ramelmeier was terminated as Executive Vice President, Technical Operations at SANGAMO THERAPEUTICS, INC.","evidence_excerpt":"the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Executive Vice President, Technical Operations"}],"fact_type":"executive_change"},{"claim_id":"c3cc50828e8c9710169a152aaa42405606649831","claim":"SANGAMO THERAPEUTICS, INC announced a restructuring with charges of approximately $5 million to $7 million affecting United States workforce and California internal manufacturing and allogeneic research footprints (approximately 120 roles in the United States, or approximately 27% of its United States workforce).","evidence_excerpt":"in the elimination of approximately 120 roles in the United States, or approximately 27% of its United States workforce. Sangamo estimates that it will incur approximately $5 million to $7 million in cash-based expenses related to employee severance and notice period payments, benefits and related restructuring costs. Sangamo expects that the majority of the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $5 million to $7 million"},{"label":"Affected area","value":"United States workforce and California internal manufacturing and allogeneic research footprints"},{"label":"Headcount","value":"approximately 120 roles in the United States, or approximately 27% of its United States workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}